Fed Chair Powell, joined by Treasury Secretary Yellen, delivers his opening statement to the Senate Banking Committee, which touched on COVID, inflation, the labor market, and GDP growth.
On Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). With the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. Billionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions.
Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 13.7% as of 11:57 a.m. ET on Monday in response to reports that a new strain of the COVID-19 virus has been identified. Indeed, headlines regarding the new omicron variant of the coronavirus began to surface before Thursday's Thanksgiving holiday. It just took a while for investors to connect the dots all the way back to Vir Biotechnology, which potentially benefits from a renewed outbreak of infections stemming from this new strain of the pandemic-causing virus.
Shares of cruise-line stocks are down again on Tuesday, with Carnival Corporation (NYSE: CCL) sliding 4.6% in 11 a.m. ET trading, and rivals Royal Caribbean (NYSE: RCL) and Norwegian Cruise Line Holdings (NYSE: NCLH) not far behind. As MarketWatch reports today, Moderna CEO Stéphane Bancel is warning that his company's Covid-19 vaccine may suffer "a material drop" in effectiveness at protecting patients from the new omicron variant of the SARS-CoV-2 coronavirus.
Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.
Those following along with Clover Health Investments, Corp. ( NASDAQ:CLOV ) will no doubt be intrigued by the recent...
Shares of Apple (NASDAQ: AAPL) stock closed up 2.2% on Monday following a holiday weekend that featured new commentary on the company and its products from Bloomberg. Last week, if you recall, Apple shares got a boost from reports that the company is planning to build an electric car with autonomous driving capability and also has an augmented reality headset in the works -- one that will be powerful enough to work as a stand-alone device. Well, over the weekend, Bloomberg expanded on these reports, adding that Apple is also working to develop augmented reality (AR) glasses (i.e., something different from the headset) and predicting that consumers (and investors) might get their first look at the AR headset as early as June 2022 if the company decides to unveil it at Apple's planned Worldwide Developers Conference next June.
Yahoo Finance Live's Julie Hyman breaks down some of the leading national headlines.
Uranium stocks are finally in the news after several years, and you don't want to miss this opportunity.
As I was extolling the virtues of Social Security’s 5.9% COLA, the Centers for Medicare and Medicaid Services (CMS) announced that they were increasing the premium for Medicare Part B by 14.5%. As a reminder, Medicare is composed of two programs. Part A, Hospital Insurance (HI), which covers inpatient hospital services, skilled nursing facilities, home healthcare, and hospice care.
Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some...
You only have a couple more days to profit in two different ways from tax-loss selling. From a statistical point of view, that means you’re finding a security whose gyrations can explain or predict at least half of the movements of your tax loss sale candidate.
Adagio Therapeutics Inc. is riding high after the company said its experimental antibody is likely to be just as effective against the omicron variant of the coronavirus as it is against previous variants. The antibody, a drug called ADG20, affords protection for up to one year, according to the firm.
Stock prices can go up and down for a number of reasons in the near term, but over many years, stocks tend to follow the underlying growth of the company. While Alibaba (NYSE: BABA) and Stitch Fix (NASDAQ: SFIX) have seen their share prices crater this year, both companies continue to post solid operating results. Here's why these growth stocks could be bargains at current prices.
CEO Satya Nadella sold about half his stake in the software company, according to recent filings with the Securities and Exchange Commission.
A big weekend for advance box office sales and a new product offering were potential good news for believers in AMC's recovery.
If you're a fan of stable healthcare companies that have the potential to pay you ever-rising dividends until the cows come home, Viatris (NASDAQ: VTRS) might well become a dream stock. The single most persuasive argument against it being too late to buy Viatris is that the company is just getting started. After all, its life as an independent entity started a mere year ago with the merger of Pfizer's generic drugs business, Upjohn, and Mylan.
Honeywell International (NASDAQ: HON) appears to be the next company in line for a breakup after its iconic peer, General Electric (NYSE: GE), announced plans to separate into three different companies over the next few years. The subject last received a highly vocal airing in 2017 when an activist hedge fund campaigned for Honeywell to spin off its aerospace business. The businesses would be valued higher by the market if management separated them than if they were still part of Honeywell.
What kind of stocks stir up controversy like no other? Penny stocks. These tickers trading for less than $5 per share have earned a reputation as some of the most divisive names on Wall Street, with these plays either met with open arms or given the cold shoulder. It’s understandable why some investors are wary. Those opposed are quick to point out that there could be a very real reason these stocks are changing hands for pocket change, with the low share prices often masking obstacles like weak
Paysafe Limited ( NYSE:PSFE ) is possibly approaching a major achievement in its business, so we would like to shine...